Back

Cost-Effectiveness of Personalized Policies for Implementing Organ-at-Risk Sparing Adaptive Radiation Therapy in Head and Neck Cancer: A Markov Decision Process Approach

Hosseinian, S.; Suarez-Aguirre, D.; Dede, C.; Garcia, R.; McCullum, L.; Hemmati, M.; Karagoz, A.; Mohamed, A. S. R.; Lai, S. Y.; Hutcheson, K. A.; Moreno, A. C.; Brock, K. K.; Nosrat, F.; Fuller, C. D.; Schaefer, A. J.; Rice/MD Anderson Center for Operations Research in Cancer (CORC), ; MD Anderson Head and Neck Cancer Symptom Working Group,

2024-11-05 oncology
10.1101/2024.11.05.24316767 medRxiv
Show abstract

PurposeTo develop a clinical decision-making model for implementation of personalized organ-at-risk (OAR)-sparing adaptive radiation therapy (ART) that balances the costs and clinical benefits of radiation plan adaptations, without limiting the number of re-plannings per patient, and derive optimal policies for head and neck cancer (HNC) radiation therapy. Methods and MaterialsBy leveraging retrospective CT-on-Rails imaging data from 52 HNC patients treated at the University of Texas MD Anderson Cancer Center, a Markov decision process (MDP) model was developed to identify the optimal timing for plan adaptations based on the difference in normal tissue complication probability ({Delta}NTCP) between the planned and delivered dose to OARs. To capture the trade-off between the costs and clinical benefits of plan adaptations, the end-treatment {Delta}NTCPs were converted to Quality Adjusted Life Years (QALYs) and, subsequently, to equivalent monetary values, by applying a willingness-to-pay per QALY parameter. ResultsThe optimal policies were derived for 96 combinations of willingness-to-pay per QALY (W) and re-planning cost (RC). The results were validated through a Monte Carlo (MC) simulation analysis for two representative scenarios: (1) W = $200,000 and RC = $1,000; (2) W = $100,000 and RC = $2,000. In Scenario (1), the MDP models policy was able to reduce the probability of excessive toxicity, characterized by {Delta}NTCP [≥] 5%, to zero (down from 0.21 when no re-planning was done) at an average cost of $380 per patient. Under Scenario (2), it reduced the probability of excessive toxicity to 0.02 at an average cost of $520 per patient. ConclusionsThe MDP models policies can significantly improve the treatment toxicity outcomes compared to the current fixed-time (one-size-fits-all) approaches, at a fraction of their costs per patient. This work lays the groundwork for developing an evidence-based and resource-aware workflow for the widespread implementation of ART under limited resources.

Matching journals

The top 2 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.